An association among iron, copper, zinc, and selenium, and antioxidative status in dyslipidemic pediatric patients with glycogen storage disease types IA and III.
Dyslipidemia in patients with glycogen storage disease types Ia (GSD Ia) and III (GSD III) does not lead to premature atherosclerosis. The aim of this study was to investigate the association among serum copper (Cu), zinc (Zn), iron (Fe), and selenium (Se) concentrations, and their carrier proteins: ceruloplasmin, albumin, and related antioxidant enzyme activities [superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), paraoxonase (PON), and arylesterase (ARYL)] in 20 GSD Ia and 14 III patients compared to age and sex matched 20 healthy subjects. Erythrocyte oxidative stress was measured by erythrocyte thiobarbituric acid reactive substances (eTBARSs). Hypertriglyceridemia [333 (36-890)mg/dL] in GSD Ia and hypercholesterolemia with elevated LDL-cholesterol [188 (91-313)mg/dL] and decreased HDL-cholesterol [32(23-58)mg/dL] levels in GSD III were found. Serum Cu, Fe, and Zn showed no significant differences between groups. However, Se 60 (54-94), 81 (57-127) microg/L, ceruloplasmin 21 (10-90), 27 (23-65) microg/L, and albumin 2.4 (1.7-5.1), 2.8 (1.8-4.06)g/dL levels were decreased in GSD Ia and III groups, respectively, in comparison with the controls [Se 110 (60-136) microg/L, ceruloplasmin 72 (32-94) microg/L, and albumin 4.4 (4-4.8)g/dL)]. In spite of high oxidative stress in erythrocyte detected by elevated eTBARS/Hb levels in GSD group [674.8 (454.6-948.2) for GSD Ia, 636.3 (460.9-842.1) for GSD III, and 525.6 (449.2-612.6)], the activities of CAT, SOD, ARYL, and PON in GSD patients were not different from the controls. GPx activity was decreased in GSD Ia [3.7 (1.8-7.1)U/mL] and GSD III [4.2 (2.2-8.6)U/mL] compared with healthy controls [7.1 (2.9-16.2)U/mL]. In conclusion, this study supplied the data for trace elements, their carrier, and antioxidative enzymes in the patients with GSD Ia and III. The trace elements and anti-oxidative enzyme levels in GSD patients failed to explain the atherosclerotic escape phenomenon reported in these patients.
Kalkan Ucar
Sema
S
Ege University Faculty of Medicine, Department of Pediatric Endocrinology and Metabolism, 35100, Bornova, Izmir, Turkey. semakalkan@hotmail.com
Coker
Mahmut
M
Sözmen
Eser
E
Goksen Simsek
Damla
D
Darcan
Sukran
S
D000293:Adolescent; D000975:Antioxidants / Q000378:metabolism*; D002648:Child; D002675:Child, Preschool; D003300:Copper / Q000097:blood; D050171:Dyslipidemias / Q000378:metabolism*; D005260:Female; D005979:Glutathione Peroxidase / Q000097:blood / Q000378:metabolism; D005953:Glycogen Storage Disease Type I / Q000378:metabolism*; D006010:Glycogen Storage Disease Type III / Q000378:metabolism*; D006801:Humans; D007223:Infant; D007501:Iron / Q000097:blood; D008297:Male; D018384:Oxidative Stress; D012643:Selenium / Q000097:blood; D014131:Trace Elements / Q000097:blood* / Q000378:metabolism; D055815:Young Adult; D015032:Zinc / Q000097:blood
D000975:Antioxidants; D014131:Trace Elements; D003300:Copper; D007501:Iron; D005979:Glutathione Peroxidase; D012643:Selenium; D015032:Zinc